Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Aug 1;51 Suppl 1(Suppl 1):S150-70.
doi: 10.1086/653065.

Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia

Infectious Diseases Society of America (IDSA)  1 ; American College of Chest Physicians (ACCP); American Thoracic Society (ATS); Society of Critical Care Medicine (SCCM); Brad Spellberg, George Talbot
Affiliations
Review

Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia

Infectious Diseases Society of America (IDSA) et al. Clin Infect Dis. .

Erratum in

  • Clin Infect Dis. 2010 Nov 1;51(9):1114
No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. B.S. has received consulting fees from Pfizer, Merck, Basilea, Arpida, Theravance, Advanced Life Sciences, and The Medicines Company; research support from Astellas, Gilead, Enzon, Novartis, Merck, and Pfizer; and speaker’s honoraria from Merck, Pfizer, and Astellas and owns shares in NovaDigm Therapeutics. Through Talbot Advisors, G.T. has provided consultative services to Actelion, Advanced Life Sciences, Avera, Bausch & Lomb, Calixa, Cempra, Cerexa, Cubist, Ipsat, Middlebrook, Nabriva, PTC, Rib-X, Shire, Targanta, Tetraphase, Theravance, ViroPharma, and Wyeth and owns shares in Calixa and Mpex.

References

    1. Emori TG, Banerjee SN, Culver DH, et al. Nosocomial infections in elderly patients in the United States, 1986–1990. National Nosocomial Infections Surveillance System. Am J Med. 1991;91:289S–293S. - PubMed
    1. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA. 1995;274:639–644. - PubMed
    1. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med. 1999;27:887–892. - PubMed
    1. McEachern R, Campbell GD., Jr Hospital-acquired pneumonia: epidemiology, etiology, and treatment. Infect Dis Clin North Am. 1998;12:761–779. - PubMed
    1. Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis. 2007;45:1179–1181. - PubMed

Publication types

Substances